Centessa Pharmaceuticals (CNTA) Interest Expenses (2022 - 2026)

Centessa Pharmaceuticals (CNTA) has 5 years of Interest Expenses data on file, last reported at $2.7 million in Q1 2026.

• Quarterly Interest Expenses fell 5.07% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (up 8.38% YoY) and the FY2025 annual result came in at $11.5 million, up 13.57% from the prior year.
• Interest Expenses fell to $2.7 million in Q1 2026 per CNTA's latest filing, from $2.8 million in the prior quarter.
• Across five years, Interest Expenses topped out at $2.9 million in Q3 2025 and bottomed at $1.5 million in Q1 2022.
• The 5-year median for Interest Expenses is $2.5 million (2024), against an average of $2.4 million.
• The widest annual swing landed in 2023, when Interest Expenses soared 56.33%; it then decreased 5.07% in 2026.
• Tracing CNTA's Interest Expenses over 5 years: stood at $2.2 million in 2022, then grew by 16.66% to $2.6 million in 2023, then slipped by 3.54% to $2.5 million in 2024, then advanced by 13.27% to $2.8 million in 2025, then retreated by 2.74% to $2.7 million in 2026.
• Per Business Quant, the three latest CNTA Interest Expenses figures stand at $2.7 million (Q1 2026), $2.8 million (Q4 2025), and $2.9 million (Q3 2025).

Peer Comparison